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Biographical Sketch  
Dr Asif Iqbal is a Birmingham Fellow in the Institute of Cardiovascular Sciences, College of 
Medical and Dental Sciences, University of Birmingham.  He has been studying the role of 
inflammation in cardiovascular disease and how we can harness endogenous mediators to 
regulate this process. Inflammation has been the central theme throughout his research, with 
particular emphasis on the anti-inflammatory mechanisms at play in both acute and chronic 
immune models of inflammation. His doctoral training focused on the galectins and their role 
in regulating leukocyte trafficking and activation of immune cells. His post-doctoral research 
was centred on the role chemokines play in monocyte and macrophage recruitment in the 
context of atherosclerosis. Following his award of a Birmingham fellowship, he now aims to 
bring these themes together; to investigate the actions of the galectins in pre-clinical models 
of vascular inflammation and atherosclerosis, and the mechanisms by which they regulate 
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Commentary on “Inhibiting inflammation with Myeloid cell-specific nanobiologics 
promotes organ transplant acceptance” by Braza et al, Immunity 2018   
 
Organ transplantation has proven to be very effective in a variety of end stage diseases. 
Immunosuppressive agents prescribed  to patients modestly improves graft survival but long 
term use can have detrimental side effects, leaving patients with increased risk of infection, 
cancer, and metabolic toxicity1. Strategies targeting adaptive immune cell tolerance 
induction have proven promising2, however long term graft survival rates still remain sub-
optimal. More recently innate immune cells, including macrophages, NK cells and 
monocytes have been identified as key players in the initiation of allograft rejection3, 4. The 
mechanisms by which macrophages mediate graft loss remain poorly understood.  
Recently, a study by Braza et al.,5 identified a macrophage activation pathway linked to 
allograft rejection. The authors utilised a novel myeloid-specific nanoimmunotherapy to 
target graft infiltrating macrophages to promote long term organ transplant acceptance. Pro-
inflammatory activation of macrophages by danger associated molecular patterns (DAMPs) 
vimentin and high mobility group box 1 (HMGB1) by  dectin-1 and TLR4 activation has been 
previously shown6, 7. Using an experimental heart transplantation mouse model, Braza et al., 
found both vimentin and HMGB1 were upregulated in allograft infiltrating macrophages; 
raising the question whether  these targets could promote “trained immunity”. Innate immune 
cells can acquire trained immunity or “innate immune memory”,  whereby secondary non-
specific challenge, after pre-exposure to certain inflammatory stimuli triggers epigenetic and 
metabolic changes, enhancing pro-inflammatory responses8. Monocytes pre-exposed to 
vimentin, followed by re-stimulation with HMGB1, increased  pro-inflammatory IL-6 and 
TNFα production in vitro. Graft-infiltrating macrophages from dectin-1 and TLR4 deficient 
mouse heart allografts produced significantly lower levels of IL-6 and TNFα  following ex-
vivo stimulation.  
To target trained macrophages therapeutically, Braza et al., utilised myeloid specific high-
density lipoproteins (HDL) nanobiologics9. The authors armed their nanobiologics with 
rapamycin, an mTOR inhibitor (termed mTORi-HDL), which has been shown to inhibit 
myeloid cell activation and pro-inflammatory cytokine production10. Heart allografts in 
recipient mice were shown to accumulate mTORi-HDL and its uptake preferentially by 
myeloid cells, namely macrophages. A treatment regime of three intravenous doses of 
mTORi-HDL was sufficient to prolong graft survival, compared to placebo control or mice 
treated with oral rapamycin. Following ex vivo stimulation it was shown that these 
macrophages had a marked reduction in pro-inflammatory cytokine production, suggesting 
trained macrophage responses were impaired because of mTORi-HDL treatment. Recipient 
allografts, blood and spleen were shown to have increased numbers of Ly6CLo 
macrophages, reported to have anti-inflammatory properties. The authors confirmed that 
Ly6CLo macrophages  inhibited T cell proliferation and promoted regulatory T cell (Treg) 
expansion in vitro, in addition, mTORi-HDL allografts were shown to have significantly 
elevated Tregs counts. Irrespective of mTORi-HDL treatment, Ly6CLo macrophage depletion 
prior to transplantation resulted in early graft rejection. Allograft survival was restored 
following adoptive transfer of wild-type monocytes, reinforcing the view that the mTORi-HDL 
therapy requires Ly6CLo regulatory macrophages for successful organ transplant 
acceptance. Finally, the authors evaluated the impact of combinational therapy with mTORi-
HDL and a CD40-CD40L targeting nanbiologic, TRAF6i-HDL11. They found that short-term 
combination therapy with mTORi-HDL/ TRAF6i-HDL synergistically promoted long-term 
allograft survival, and significantly outperformed either monotherapy.         
The study by Braza et al., clearly highlights the importance of innate immune signalling in 
driving trained immunity and excessive inflammation. Taking atherosclerosis as an example, 
Bekkering et al.,12 found that exposing monocytes to a low concentration of oxLDL  drove a 
trained proatherogenic macrophage phenotype characterised by increased pro-inflammatory 
cytokine production and foam cell formation. A review by Zhang and colleagues13 
emphasised the importance of  trained macrophage activation pathways in pathological 
conditions such as cardiac remodelling and ischaemic heart disease. A recent review by 
Kusters and colleagues14 reiterated the importance of immune checkpoint molecules and 
their potential as therapeutic targets in atherosclerosis. The concept of targeting immune 
checkpoint molecules,  such as CD40-CD40L, as chosen by Braza et al., or others, like 
CD80/86-CD28, is not a novel concept in of itself. However, the use of nanobiologics to 
successfully administer high local doses of immunosuppressive agents while limiting 
systemic toxicity proves to be a very attractive modality of treatment and  could very well 
breathe life into current treatment regimens and combinatorial therapies in the treatment of 
multiple chronic inflammatory diseases.  
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